Ontology highlight
ABSTRACT: Background
The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection. However, chemotherapy resistance is associated with a poor prognosis. The prognostic impact of high blood sugar levels on oxaliplatin resistance in CRC patients is an unexplored topic.Methods
In total, 157 patients with stage III CRC were classified according to their fasting blood sugar level (?126 or <126?mg/dl). Clinicopathological features and oxaliplatin chemoresistance/survival outcome of the two groups were compared. In vitro cell proliferation assay was performed through d-(+)-glucose administration.Results
Multivariate analysis results revealed that high blood sugar level was a significantly independent prognostic factor of disease-free survival and overall survival (both p?p?ConclusionsHyperglycemia can affect clinical outcomes in stage III CRC patients receiving adjuvant chemotherapy, and the mechanism underlying oxaliplatin resistance is possibly associated with increased phosphorylation of SMAD3 and MYC and upregulation of EHMT2 expression.
SUBMITTER: Yang IP
PROVIDER: S-EPMC6704420 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Yang I-Ping IP Miao Zhi-Feng ZF Huang Ching-Wen CW Tsai Hsiang-Lin HL Yeh Yung-Sung YS Su Wei-Chih WC Chang Tsung-Kun TK Chang Se-Fen SF Wang Jaw-Yuan JY
Therapeutic advances in medical oncology 20190820
<h4>Background</h4>The high prevalence of type 2 diabetes mellitus (DM) among patients with colorectal cancer (CRC) is becoming a serious public health concern worldwide. FOLFOX4 chemotherapy is one of the most widely used adjuvant therapies in patients with stage III colon cancer after surgical resection. However, chemotherapy resistance is associated with a poor prognosis. The prognostic impact of high blood sugar levels on oxaliplatin resistance in CRC patients is an unexplored topic.<h4>Meth ...[more]